Laronix Unveils Innovative Voice Restoration Study for ICU Patients at GBMC

Laronix, Inc., an established player in the medical technology field, has recently announced an important study aimed at restoring voice capabilities in patients within intensive care units (ICUs). This initiative, executed in partnership with the Greater Baltimore Medical Center (GBMC), involves Laronix's cutting-edge device, MIRA Voice, which has previously enabled patients who have undergone laryngectomies to communicate effectively. The ongoing study, primarily situated in the Milton J. Dance Jr. Head and Neck Center, will explore the potential of MIRA Voice for patients who lose their ability to speak due to intubation or tracheostomy procedures.

The Importance of the Study

Voice loss in ICU patients is a critical issue, with research revealing that over 6 million individuals are admitted to ICUs each year in the U.S. Alarmingly, up to 40% of these patients are placed on mechanical ventilation, which renders them unable to communicate verbally. The focus of this study is to explore whether the MIRA Voice device can help alleviate this barrier, facilitating better communication between patients and healthcare providers in high-stress environments.

Mousa Ahmadi, PhD and Chief Operating Officer of Laronix, emphasizes the significance of this research, highlighting that it is the first exploratory study involving the MIRA Voice for addressing ICU voice loss—a condition that affects many yet remains understudied. The goal is not only to enhance patient communication but also to help healthcare providers deliver more efficient and effective care in critical situations.

Key Features of MIRA Voice

The MIRA Voice device utilizes advanced technology that mimics human voice generation through a computer-controlled artificial lung system and synthetic vocal folds. It delivers customizable voice outputs, with options for both male and female tones, making it a versatile solution for patients who previously had limited options for voice restoration. The study, slated for completion by mid-2026, will involve around 12 participants. Researchers will assess whether MIRA Voice can help patients articulate their immediate needs and maintain casual conversations, an essential aspect of the healing and recovery process.

Financial Implications and Wider Benefits

Addressing communication barriers within ICUs can lead to considerable financial benefits, with estimates suggesting that it could save the healthcare system up to $1.4 billion annually. By reducing misunderstandings and communication delays, MIRA Voice may streamline workflows among ICU teams, ultimately improving overall patient care.

Bushra Lohrasbi, MA, CCC-SLP, a speech-language pathologist involved in the study, acknowledges that the inability to communicate significantly hinders patient experience in ICUs. She underscores that technological advancements like MIRA Voice offer a promising avenue for restoring verbal communication capabilities, which may not only enhance patient comfort but also improve clinician efficiency.

Continuous Collaboration and Future Endeavors

This study builds upon Laronix's previous partnership with GBMC, which started in 2024 with AVA Voice, a pioneering voice solution developed for laryngectomy patients, making GBMC the first global healthcare institution to leverage this innovative technology. This collaboration represents a commitment to improving the quality of life for those suffering from voice loss, showcasing the potential of voice restoration technologies in the realm of critical care.

With MIRA Voice, Laronix is poised to make significant strides in health technology, potentially transforming how voice restoration is approached in both ICU settings and beyond, all while emphasizing the company’s mission to restore communication and improve patient well-being across the globe.

About GBMC HealthCare

Founded in 1965, GBMC has earned its reputation as a premier independent community hospital. It combines the merits of both community and university-level medicine, featuring a 257-bed capacity that handles thousands of admissions and emergency visits each year. Through its comprehensive care model, GBMC aims to provide high-quality, culturally competent services to all patients.

About Laronix

Headquartered in Brisbane, Australia, Laronix is a MedTech company specializing in AI-driven voice restoration technologies aimed at addressing the needs of individuals facing voice loss. The company is working relentlessly to bring innovative solutions to the 150 million individuals globally suffering from such conditions. For more information, visit laronix.com.